{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:42:09Z","timestamp":1780051329073,"version":"3.53.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.urolonc.2025.08.022","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:58:52Z","timestamp":1758949132000},"page":"696.e9-696.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab plus gemcitabine\u2013cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial"],"prefix":"10.1016","volume":"43","author":[{"given":"Yoshihiko","family":"Tomita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.08.022_bib0001","series-title":"Global cancer observatory: cancer today (version 1.1)","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0003","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0004","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bju.12238","article-title":"Predictive factors for worse pathological outcomes of upper tract urothelial carcinoma: experience from a nationwide high-volume centre in China","volume":"112","author":"Chen","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1031774","article-title":"The lowest level of tumor involvement is a significant prognostic factor for upper tract urothelial carcinoma after radical nephroureterectomy: a large retrospective cohort study","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0006","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3390\/cancers16061115","article-title":"Upper tract urothelial cancer: guideline of guidelines","volume":"16","author":"Pandolfo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0007","doi-asserted-by":"crossref","first-page":"788.e7","DOI":"10.1016\/j.urolonc.2021.07.001","article-title":"The effect of race on stage at presentation and survival in upper tract urothelial carcinoma","volume":"39","author":"Coll\u00e0 Ruvolo","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0008","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5430\/jst.v4n2p25","article-title":"Systemic therapy for bladder cancer - a medical oncologist\u2019s perspective","volume":"4","author":"Teply","year":"2014","journal-title":"J Solid Tumors"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0010","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"Von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0011","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"Von Der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0012","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0013","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0014","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. n.d. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40."},{"key":"10.1016\/j.urolonc.2025.08.022_bib0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-021-00876-7","article-title":"The incidence and prevalence of upper tract urothelial carcinoma: a systematic review","volume":"21","author":"Soualhi","year":"2021","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0016","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1073\/pnas.1119920109","article-title":"Aristolochic acid-associated urothelial cancer in Taiwan","volume":"109","author":"Chen","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0017","article-title":"Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference","author":"Yang","year":"2014","journal-title":"Biomed Res Int 2014"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0018","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2020.38.6_suppl.551","article-title":"IMvigor130 clinical trial in patients (pts) with metastatic urothelial carcinoma (mUC): analysis of upper tract (UT) and lower tract (LT) subgroups","volume":"38","author":"De Santis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0019","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.08.022_bib0021","doi-asserted-by":"crossref","first-page":"S1507","DOI":"10.1016\/j.annonc.2024.10.289","article-title":"269O Enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC): pan-Asian subgroup analysis from EV-302\/KEYNOTE-A39","volume":"35","author":"Kikuchi","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:17:21Z","timestamp":1772882241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1078143925003412"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.022","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab plus gemcitabine\u2013cisplatin for previously untreated unresectable or metastatic urothelial carcinoma: an Asian subgroup analysis from the global phase 3 CheckMate 901 trial","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}